Controversial FDA Regulator Prasad Exits Agency Amid Backlash
TL;DR Summary
Vinay Prasad is set to leave the FDA for the second time, with his tenure marked by controversy, including a rejected mRNA vaccine, a controversial demand for an extra trial on a Huntington’s gene therapy from UniQure, public clashes with the company and alleged staff abuse, drawing mixed reactions from biotech investors and patient advocates as a replacement is named.
- Trump’s divisive FDA vaccine regulator self-destructs, will exit agency (again) Ars Technica
- FDA vaccine head will step down in April after string of controversial decisions CNBC
- Prasad out at FDA after a number of public fights with drugmakers CIDRAP
- 5 lessons from Vinay Prasad’s turbulent tenure at the FDA statnews.com
- Prasad’s Departure Could Be ‘Big Win’ for Biotech—Especially Rare Disease Space: Analysts BioSpace
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
5 min
vs 6 min read
Condensed
95%
1,103 → 60 words
Want the full story? Read the original article
Read on Ars Technica